Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EUROPEAN STUDY GROUP FOR PANCREATIC CANCER - TRIAL 4. Combination versus single agent chemotherapy in resectable pancreatic ductal and peri-ampullary cancers

Next Previous
X
Search
Trial Profile

EUROPEAN STUDY GROUP FOR PANCREATIC CANCER - TRIAL 4. Combination versus single agent chemotherapy in resectable pancreatic ductal and peri-ampullary cancers

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Gemcitabine (Primary) ; Fluorouracil; Folinic acid
  • Indications Adenocarcinoma; Pancreatic cancer; Periampullary cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ESPAC-4

    • Most Recent Events

    • 21 Sep 2022 The trial has been discontinued in Finland, according to European Clinical Trials Database record.
    • 10 Apr 2021 Results assessing digital quantification of GATA6 immunohistochemistry association with overall survival and pancreatic adenocarcinoma specimens were obtained from patients enrolled in two clinical studies: ESPAC-3 and ESPAC-4 presented at the 112th Annual Meeting of the American Association for Cancer Research
    • 31 May 2020 Primary endpoint (Length of survival.) has been met presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top